this post was submitted on 22 Jun 2025
9 points (100.0% liked)

Futurology

3068 readers
40 users here now

founded 2 years ago
MODERATORS
voidx@futurology.today
Lugh@futurology.today
Espiritdescali@futurology.today
AwesomeLowlander@futurology.today
9
Verve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. (investor.lilly.com)
submitted 1 month ago by Lugh@futurology.today to c/futurology@futurology.today
1 comments fedilink hide all child comments
top 1 comments
sorted by: hot top controversial new old
[–] Riffraffintheroom@hexbear.net 1 points 1 month ago

That’s cool but I expect to never hear about this again ever.